The dynamics of monkeypox transmission

Abstract

BMJ is committed to ensuring the independence and integrity of our content, products, and services. We strive, therefore, to be transparent about any interests that our users, customers, and partners might want to know about. This policy on declaration of interests applies to everyone involved in the conception, creation, and delivery of our content, products, and services. What interests should I declare?We want to hear about interests that might conflict with the work you are doing or have been asked to do for BMJ. A conflict of interest arises when a person has a personal or organisational interest that may influence or appear to influence the work they are doing. Usually this is a financial interest, but it may also be non-financial.Above all we want transparency about any personal or organisational interests that might be seen as a conflict of interest in relation to the task a person is being asked to do for BMJ.The BMJ's policy announced in 2014 (http://www.bmj.com/content/349/bmj.g7197) prohibits authors with relevant financial ties to industry from writing editorials clinical reviews, minerva pictures, endgames and practice articles (excluding therapeutics articles). By "industry" we mean companies producing drugs, devices, or tests; medical education companies; or other companies with an interest in the topic of the article.

Mpox: a new outbreak of a once exotic infection

“…Between May and August 2022, more than 70,000 people worldwide had contracted mpox. Of these, 99% were in countries without previous known endemic spread of mpox 1 . But the true size of the pandemic remains unclear: “Documentation of infection may not be as good in some parts of the world as it is in the UK and the USA,” Professor Phillips comments.…”

“…The number of new mpox infections now seems to be declining. But, as a recent paper notes, “Whether this marks the end of the outbreak or whether intermittent surges will continue is not yet clear.” 1 …”

“…But, as a recent paper notes, "Whether this marks the end of the outbreak or whether intermittent surges will continue is not yet clear." 1 "We're now moving in the right direction with new mpox case numbers dropping significantly," says Dr Sophia Makki, Incident Director at the UK Health Security Agency (UKHSA). "[Nevertheless,] It's vital people remain alert to the risk mpox poses and continue to take action to protect themselves and others.…”

Rapid Detection of the Monkeypox Virus Genome and Antigen Proteins Based on Surface-Enhanced Raman Spectroscopy

“…As of February 6, 2023, 85,645 laboratory-confirmed cases and 1381 suspected cases have been reported worldwide . Additionally, 99% of cases occur in countries where MPXV was not previously endemic . There is no specific treatment for MPXV infection. , Therefore, early detection is the global consensus for preventing and controlling this epidemic …”

Presymptomatic viral shedding in high‐risk mpox contacts: A prospective cohort study

“…13 Nevertheless, presymptomatic shedding of MPXV, the body sites from which it may occur and its timing in relation to the onset of symptoms remain elusive. 14 To study the risk of infection after exposure to MPXV and the natural history of the early phase of MPXV infection, we performed a detailed follow-up of high-risk contacts of clade IIb MPXV infected patients. Here, we describe their clinical and virological characteristics from exposure until potential diagnosis.…”